Literature DB >> 12091261

Estimating the relationship between disease progression and cost of care in dementia.

J Wolstenholme1, P Fenn, A Gray, J Keene, R Jacoby, T Hope.   

Abstract

BACKGROUND: Previous studies have shown a positive relationship between disease severity and cost. AIMS: To explore the factors affecting time to institutionalisation and estimate the relationship between the costs of care and disease progression.
METHOD: Retrospective analysis of a longitudinal data-set for a cohort of 100 patients diagnosed with Alzheimer's disease or vascular dementia.
RESULTS: Changes in both Mini-Mental State Examination (MMSE) and Barthel scores have independent and significant marginal effects on costs. Each one-point decline in the MMSE score is associated with a pound sterling 56 increase in the four-monthly costs, whereas each one-point fall in the Barthel index is associated with a pound sterling 586 increase in costs.
CONCLUSIONS: It may be inappropriate for economic models of disease progression in dementia to be based solely on measures of cognitive change. MMSE and the Barthel index are independent significant predictors of time to institutionalisation and cost of care, but changes in the Barthel index are particularly important in predicting costs outside institutional care.

Entities:  

Mesh:

Year:  2002        PMID: 12091261     DOI: 10.1192/bjp.181.1.36

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  20 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

3.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 6.  A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Authors:  Joanna Kirby; Colin Green; Emma Loveman; Andrew Clegg; Joanna Picot; Andrea Takeda; Elizabeth Payne
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

Authors:  Colin Green
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Non-pharmacological cognitive intervention for aging and dementia: Current perspectives.

Authors:  Jorge Alves; Rosana Magalhães; Alvaro Machado; Oscar F Gonçalves; Adriana Sampaio; Agavni Petrosyan
Journal:  World J Clin Cases       Date:  2013-11-16       Impact factor: 1.337

Review 10.  The cost of dementia in Europe: a review of the evidence, and methodological considerations.

Authors:  Linus Jönsson; Anders Wimo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.